BCG 005
Alternative Names: BCG-005Latest Information Update: 29 Jul 2022
At a glance
- Originator Beijing Biocytogen
- Developer Beijing Biocytogen; LiberoThera
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CCR8 receptor antagonists; Regulatory T-lymphocyte inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Solid tumours
Most Recent Events
- 20 Jul 2022 Early research in Solid tumours in China (Parenteral) (Beijing Biocytogen website, July 2022)